biotech · Hypertrophic Cardiomyopathy · Arrhythmogenic Right Ventricular Cardiomyopathy · TNYA
Tenaya Therapeutics
Tenaya Therapeutics patent portfolio — 13 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- South San Francisco, USA
- Founded
- 2016
- Employees
- 99
- Programs
- 2
- Drugs
- 1
- Patents
- 13
Tenaya Therapeutics patents
13 pharmaceutical patents indexed for Tenaya Therapeutics. 0 expire within 24 months.
Tenaya Therapeutics has 13 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12312345
Fluoroalkyl-oxadiazoles and uses thereof
granted -
US 12201617
HDAC6 inhibitors for treatment of metabolic disease and HFpEF
granted -
US 12168778
Cardiac cell reprogramming with myocardin and ASCL1
granted -
US 12151001
Optimized expression cassettes for gene therapy
granted -
US 12104165
Adeno-associated virus with engineered capsid
granted -
US 11926622
Fluoroalkyl-oxadiazoles and uses thereof
granted -
US 11913012
Cardiac cell reprogramming with myocardin and ASCL1
granted -
US 11781156
Plakophillin-2 gene therapy methods and compositions
granted -
US 11759531
Gene therapy vectors for treating heart disease
granted -
US 11578066
Fluoroalkyl-oxadiazoles and uses thereof
granted -
US 11446397
Gene therapy vectors for treating heart disease
granted -
US 11129908
Gene therapy vectors for treating heart disease
granted -
US 11015211
Cardiac cell reprogramming with myocardin and ASCL1
granted
Frequently asked questions
How many patents does Tenaya Therapeutics have?
13 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Tenaya Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.